These therapies are prescribed only after a thorough medical evaluation and discussion of potential risks, benefits, and alternatives
Both albiglutide and dulaglutide received FDA approval for the treatment of T2DM in 2014, with dulaglutide having an additional indication since 2020 to reduce the risk of major adverse cardiovascular events (MACE) in adults with T2DM and established cardiovascular disease or multiple cardiovascular risk factors [ Table 2 ]
Research indicates that semaglutide is not detectable in the breast milk of mothers who take the medication subcutaneously (under the skin)
Summary: Ozempic does not directly cause missed periods, but the weight loss it produces can indirectly disrupt menstrual cycles through hormonal and metabolic changes affecting the hypothalamic-pituitary-ovarian axis
B12 addresses specific vulnerabilities that come with GLP-1 receptor agonist therapy, from nausea at initiation to nutrient absorption deficits that develop over months of use
Zinc deficiency: its characterization and treatment